← Back to All US Stocks

Gelstat Corp. (GSAC) Fundamental Analysis & AI Grade 2026

GSAC OTC Pharmaceutical Preparations DE CIK: 0000890725
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Gelstat Corp. (GSAC) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

GSAC Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

GSAC vs Healthcare Sector: How Gelstat Corp. Compares

How Gelstat Corp. compares to Healthcare sector averages

Net Margin
GSAC 0.0%
vs
Sector Avg 12.0%
GSAC Sector
ROE
GSAC 0.0%
vs
Sector Avg 15.0%
GSAC Sector
Current Ratio
GSAC 0.0x
vs
Sector Avg 2.0x
GSAC Sector
Debt/Equity
GSAC 0.0x
vs
Sector Avg 0.6x
GSAC Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Gelstat Corp. Stock Overvalued? GSAC Valuation Analysis 2026

Based on fundamental analysis, Gelstat Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Gelstat Corp. Balance Sheet: GSAC Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

GSAC Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

GSAC SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Gelstat Corp. (CIK: 0000890725)

📋 Recent SEC Filings

Date Form Document Action
Mar 8, 2022 4 xslF345X03/ownership.xml View →
Nov 21, 2012 10-K/A gelstat10ka.htm View →
Nov 21, 2012 10-K/A gelstat10ka.htm View →
Oct 22, 2012 10-K gelstat10k.htm View →
Oct 22, 2012 10-Q gelstat10q3.htm View →

Frequently Asked Questions about GSAC

What is the AI rating for GSAC?

Gelstat Corp. (GSAC) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are GSAC's key strengths?

Claude: Analysis in progress.

What are the risks of investing in GSAC?

Claude: Analysis in progress.

What is GSAC's revenue and growth?

Gelstat Corp. reported revenue of N/A.

Does GSAC pay dividends?

Gelstat Corp. does not currently pay dividends.

Where can I find GSAC SEC filings?

Official SEC filings for Gelstat Corp. (CIK: 0000890725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is GSAC's EPS?

Gelstat Corp. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is GSAC's fundamental grade?

Based on our AI fundamental analysis in May 2026, Gelstat Corp. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is GSAC stock overvalued or undervalued?

Valuation metrics for GSAC: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is GSAC's AI grade for 2026?

Our dual AI analysis gives Gelstat Corp. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is GSAC's free cash flow?

Gelstat Corp.'s operating cash flow is N/A, with capital expenditures of N/A.

How does GSAC compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI